Supernus Pharmaceuticals | SUPN - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Abbott USD 3.27B 138M 2026-03
ANI Pharmaceuticals USD 82.79M 6.13M 2025-12
Aurora Cannabis CAD 40.62M 1.17M 2025-12
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Canopy Growth CAD 28.9M 636K 2025-12
Cara Therapeutics USD 2.19M 2.45M 2025-09
Corcept Therapeutics USD 128.04M 13.3M 2026-03
Eisai JPY 111.72B 7.86B 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Novo Nordisk DKK 17.44B 1.41B 2025-12
Pacira USD 83.88M 7.99M 2026-03
Perrigo USD 255.9M 10.2M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
Supernus Pharmaceuticals USD 118.23M 4.16M 2026-03
United Therapeutics USD 190.6M 38.6M 2025-12
Xeris Pharmaceuticals USD 42.64M 3.82M 2025-12